Britannica
Sources used in this answer
- Prescription drug costs - Patient costs
- Prescription drug costs - Presidential actions and legislation
- Prescription drug costs - Pro 2: The government should regulate companies with private interests that result in price gouging, higher drug prices, and limited access to much-needed medicine.
- Prescription drug costs - Sources
- Prescription drug costs - Con 1: Regulation of drug prices reduces the revenue needed for the research and development of new drugs
- pharmaceutical industry - Drug patents
How do pharmaceutical companies set prescription drug prices in the United States?
Created from Britannica articles
using AI.
AI can make mistakes, so verify using Britannica articles.
pharmaceutical industry
A technician withdrawing deep-frozen cells for in vitro culture at a laboratory of a German pharmaceutical company.
In the United States, the pricing of prescription drugs is a complex process involving multiple stakeholders, primarily driven by the pharmaceutical companies that develop or acquire the medications.1
The Pricing Process
- Pharmaceutical Companies: These firms set the initial price for a drug they have developed or purchased. During the life of a patent, a company holds exclusive rights to market the drug, which allows them to charge higher prices to recoup significant research and development (R&D) costs.12
- Pharmacy Benefit Managers (PBMs): These entities negotiate rebates and savings with manufacturers on behalf of health insurance companies, Medicare plans, and large employers. These agreements are generally not publicly disclosed, making the actual cost savings to patients difficult to determine.13
- Health Insurance Companies: Insurers determine which drugs are approved for their customers, the portion of the cost they will cover, and the resulting out-of-pocket costs for the patient.1
Market Dynamics and Regulation
The U.S. market often sees higher drug prices compared to other nations. While companies argue that high prices are necessary to fund R&D and sustain long-term growth, critics argue that lack of regulation can lead to price gouging. Recent legislative efforts have sought to increase transparency, such as mandates requiring PBMs to pass rebates to health plans and the implementation of flat-fee payment structures to discourage the promotion of higher-priced drugs.1345